|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.08 USD | -0.09% |
|
-1.49% | +10.59% |
| 12-02 | Catalyst Pharmaceuticals, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 01:00 PM | |
| 11-07 | Catalyst Pharmaceuticals, Inc., Q3 2025 Earnings Call, Nov 06, 2025 |
| Capitalization | 2.84B 2.43B 2.27B 2.12B 3.96B 255B 4.29B 26.69B 10.3B 120B 10.65B 10.42B 439B | P/E ratio 2025 * |
14.6x | P/E ratio 2026 * | 12.9x |
|---|---|---|---|---|---|
| Enterprise value | 2.08B 1.79B 1.67B 1.56B 2.9B 187B 3.15B 19.59B 7.56B 88.4B 7.82B 7.65B 322B | EV / Sales 2025 * |
3.6x | EV / Sales 2026 * | 2.9x |
| Free-Float |
94.02% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Catalyst Pharmaceuticals, Inc.
| 1 day | -0.09% | ||
| 1 week | -1.49% | ||
| Current month | -1.41% | ||
| 1 month | +8.15% | ||
| 3 months | +16.57% | ||
| 6 months | -8.74% | ||
| Current year | +10.59% |
| 1 week | 22.42 |  | 23.24 |
| 1 month | 20.66 | | 23.92 |
| Current year | 19.05 | | 26.58 |
| 1 year | 19.05 | | 26.58 |
| 3 years | 11.09 | | 26.58 |
| 5 years | 3.27 | | 26.58 |
| 10 years | 0.51 | | 26.58 |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Daly
CEO | Chief Executive Officer | 64 | 31/12/2023 |
Michael Kalb
DFI | Director of Finance/CFO | 54 | 31/12/2023 |
| Chief Tech/Sci/R&D Officer | 61 | 31/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Patrick McEnany
CHM | Chairman | 77 | 31/12/2001 |
David Tierney
BRD | Director/Board Member | 61 | 30/09/2002 |
Richard Daly
BRD | Director/Board Member | 64 | 18/02/2015 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 1.05% | 29 M€ | +7.69% | - |
| 0.32% | 22 M€ | +1.44% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.09% | -1.49% | +5.10% | +33.64% | 2.84B | |
| -0.12% | -7.88% | -4.17% | -5.69% | 74.16B | |
| -0.81% | -1.18% | -34.65% | -38.63% | 59.32B | |
| +0.04% | +0.59% | +27.57% | +224.01% | 53.15B | |
| +1.57% | +68.00% | +68.00% | +68.00% | 52.8B | |
| +0.68% | +0.02% | +13.09% | -39.12% | 26.7B | |
| -2.57% | -3.24% | +141.83% | +228.11% | 20.6B | |
| -1.02% | -4.91% | +34.63% | +20.85% | 19.72B | |
| -0.57% | -0.38% | +63.21% | +1,310.33% | 18.85B | |
| +0.82% | +4.24% | +175.87% | +689.44% | 14.41B | |
| Average | -0.22% | -1.06% | +49.05% | +249.09% | 34.25B | |
| Weighted average by Cap. | -0.08% | -1.39% | +30.32% | +150.56% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 578M 496M 463M 433M 806M 51.91B 873M 5.44B 2.1B 24.53B 2.17B 2.12B 89.43B | 620M 531M 497M 464M 864M 55.65B 936M 5.83B 2.25B 26.29B 2.33B 2.28B 95.88B |
| Net income | 200M 172M 160M 150M 279M 17.97B 302M 1.88B 726M 8.49B 751M 735M 30.97B | 232M 199M 186M 173M 323M 20.81B 350M 2.18B 841M 9.83B 869M 851M 35.85B |
| Net Debt | -754M -647M -605M -565M -1.05B -67.74B -1.14B -7.1B -2.74B -32.01B -2.83B -2.77B -117B | -1.04B -893M -835M -780M -1.45B -93.53B -1.57B -9.8B -3.78B -44.19B -3.91B -3.82B -161B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/12/25 | 23.08 $ | -0.09% | 960,886 |
| 03/12/25 | 23.10 $ | +2.12% | 1,036,497 |
| 02/12/25 | 22.62 $ | -0.31% | 1,036,968 |
| 01/12/25 | 22.69 $ | -3.08% | 1,184,296 |
| 28/11/25 | 23.41 $ | -0.09% | 527,443 |
Delayed Quote Nasdaq, December 04, 2025 at 09:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CPRX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition